ArticleIndian journal of sexually transmitted diseases and AIDS
A clinico-epidemiological study of the mucocutaneous manifestations among people living with human immunodeficiency virus attending a tertiary care center in South India.
Article in Indian journal of sexually transmitted diseases and AIDS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human immunodeficiency virus (HIV) was first discovered in 1983 and has since claimed around 40.4 million lives globally as of 2022. This alarming figure highlights the potential for HIV to escalate into a severe global health crisis if not properly managed. The virus is linked to various mucocutaneous manifestations, which can serve as early indicators of HIV infection and provide prognostic insights into disease progression. These conditions can significantly impact the quality of life and, in severe cases, may even be life-threatening. Aims and Objectives: This study was done to understand the clinico-epidemiological profile of mucocutaneous manifestations in HIV patients attending Dermatology, Venereology, and Leprosy (DVL) Outpatient Department (OPD) and to analyze the demography, risk factors, CD4 counts, and their correlation with different mucocutaneous manifestations. Materials and Methods: The present study is a retrospective observational study conducted in HIV-positive patients who attended the OPD of the DVL Department of Government General Hospital, Khammam, for a period of 3 years, i.e., from January 2021 to December 2024. Patient records were retrieved electronically from the database. Clinical and demographic data were collected and laboratory investigations wherever necessary were done. Results: Out of a total of 8216 patients who attended the DVL OPD during this period, 2017 (2.3%) were tested positive for HIV. Of these, 1755 (87.01%) patients had mucocutaneous manifestations, in which 1056 patients (60%) had infectious mucocutaneous manifestations, 636 patients (36.2%) had noninfectious manifestations and 63 patients (3.8%) had antiretroviral therapy-associated drug eruptions. The study had more males (52.4%) followed by females (46.9%) and transgenders (0.7%). It is observed that the middle-aged population (21-40 years), as expected, have the majority of patients (57.19%), whereas <10 years (1.02%) had the least, with the youngest being 1 year and the oldest being 80 years. Conclusion: The study highlights that mucocutaneous manifestations correlate with CD4 count and can aid in early HIV diagnosis and monitoring, especially where CD4 testing is unavailable. Understanding their epidemiological distribution helps design targeted awareness, screening, and prevention programs for high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.